Staplin, N., Mayne, M., Abat, S., Abd Rahman, R., Abdul Cader, R., Abdul Hafidz, M., . . . Judge, P. (2023). Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: Secondary analyses of the EMPA-KIDNEY trial. Elsevier.
Цитирование в стиле Чикаго (17-е изд.)Staplin, N., et al. Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY Trial. Elsevier, 2023.
Цитирование MLA (9-е изд.)Staplin, N., et al. Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY Trial. Elsevier, 2023.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.